gene expression profiling with foundationone r cdx Search Results


foundationone cdx  (Foundation Medicine Inc)
99
Foundation Medicine Inc foundationone cdx
Foundationone Cdx, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gene+expression+profiling+with+foundationone+r+cdx/FoundationOne+CDx/pm38606821-74-8-10
Average 99 stars, based on 1 article reviews
foundationone cdx - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
foundationone liquid cdx ngs  (Foundation Medicine Inc)
97
Foundation Medicine Inc foundationone liquid cdx ngs
a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The <t>FoundationOne</t> liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.
Foundationone Liquid Cdx Ngs, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gene+expression+profiling+with+foundationone+r+cdx/FoundationOne+Liquid+CDx/pmc09941792-39-9-13
Average 97 stars, based on 1 article reviews
foundationone liquid cdx ngs - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
foundationone cdx sophia genetics  (Sophia Genetics)
97
Sophia Genetics foundationone cdx sophia genetics
a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The <t>FoundationOne</t> liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.
Foundationone Cdx Sophia Genetics, supplied by Sophia Genetics, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gene+expression+profiling+with+foundationone+r+cdx/Blood+cancers/10__1016_slash_j__dscb__2024__100126-69-31-33
Average 97 stars, based on 1 article reviews
foundationone cdx sophia genetics - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
foundationone liquid cdx  (Johns Hopkins HealthCare)
90
Johns Hopkins HealthCare foundationone liquid cdx
a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The <t>FoundationOne</t> liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.
Foundationone Liquid Cdx, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gene+expression+profiling+with+foundationone+r+cdx/foundationone+liquid+cdx/10__1200_slash_po__24__00254-28-34-46
Average 90 stars, based on 1 article reviews
foundationone liquid cdx - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
foundationone heme  (Foundation Medicine Inc)
95
Foundation Medicine Inc foundationone heme
a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The <t>FoundationOne</t> liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.
Foundationone Heme, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gene+expression+profiling+with+foundationone+r+cdx/FoundationOne+Heme/custom%40foundationone-heme%4010%2E1055%2Fs-0045-1805022
Average 95 stars, based on 1 article reviews
foundationone heme - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
foundationone assay  (Neoplus inc)
90
Neoplus inc foundationone assay
a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The <t>FoundationOne</t> liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.
Foundationone Assay, supplied by Neoplus inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gene+expression+profiling+with+foundationone+r+cdx/foundationone+assay/pm32119917-241-8-13
Average 90 stars, based on 1 article reviews
foundationone assay - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
foundationone cdx  (NantHealth)
90
NantHealth foundationone cdx
a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The <t>FoundationOne</t> liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.
Foundationone Cdx, supplied by NantHealth, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gene+expression+profiling+with+foundationone+r+cdx/foundationone+cdx/pm34606929-28-2-28
Average 90 stars, based on 1 article reviews
foundationone cdx - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
tissue genotyping and liquid biopsy tests plasmaselect ps  (PlasmaSelect ag)
90
PlasmaSelect ag tissue genotyping and liquid biopsy tests plasmaselect ps
a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The <t>FoundationOne</t> liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.
Tissue Genotyping And Liquid Biopsy Tests Plasmaselect Ps, supplied by PlasmaSelect ag, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gene+expression+profiling+with+foundationone+r+cdx/tissue+genotyping+and+liquid+biopsy+tests+plasmaselect+ps/pmc06114875-17-9-14
Average 90 stars, based on 1 article reviews
tissue genotyping and liquid biopsy tests plasmaselect ps - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
foundationone cdx  (Pfizer Inc)
86
Pfizer Inc foundationone cdx
a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The <t>FoundationOne</t> liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.
Foundationone Cdx, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gene+expression+profiling+with+foundationone+r+cdx/dx+oncominetm+target+test/sec_filing____1488613_slash_000156459018004758_slash_fmi___10k_20171231-164-14-26
Average 86 stars, based on 1 article reviews
foundationone cdx - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
foundationone liquid cdx  (Guardant Health)
86
Guardant Health foundationone liquid cdx
a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The <t>FoundationOne</t> liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.
Foundationone Liquid Cdx, supplied by Guardant Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gene+expression+profiling+with+foundationone+r+cdx/cdx+foundationone+liquid/pmc12607388-32-19-17
Average 86 stars, based on 1 article reviews
foundationone liquid cdx - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
foundationone cdx  (Chugai)
86
Chugai foundationone cdx
a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The <t>FoundationOne</t> liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.
Foundationone Cdx, supplied by Chugai, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gene+expression+profiling+with+foundationone+r+cdx/cdx+foundationone/pm41128349-53-16-19
Average 86 stars, based on 1 article reviews
foundationone cdx - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
genome profiling test foundationone®cdx  (GenPro Inc)
90
GenPro Inc genome profiling test foundationone®cdx
a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The <t>FoundationOne</t> liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.
Genome Profiling Test Foundationone®Cdx, supplied by GenPro Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gene+expression+profiling+with+foundationone+r+cdx/foundationone++cdx+cancer+genome+profiling/pmc10808907-91-1-2
Average 90 stars, based on 1 article reviews
genome profiling test foundationone®cdx - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The FoundationOne liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.

Journal: Case Reports in Oncology

Article Title: Utilizing Liquid Biopsy for Treatment Management in Bone-Dominant Metastatic Breast Cancer: A Case Report

doi: 10.1159/000526642

Figure Lengend Snippet: a The timeline of Patient 1. The second Guardant360 liquid biopsy on September 2021 revealed a PIK3CA E452K-targetable mutation. b The timeline of Patient 2. The FoundationOne liquid biopsy on January 2019 and the following tissue biopsy on January 2019 both revealed a PIK3CA E545K mutation. FAC, doxorubicin, cyclophosphamide, and fluorouracil; T, paclitaxel; OFS, ovarian function suppression; AI, aromatase inhibitor; SERD, selective estrogen receptor degrader.

Article Snippet: After another 4 years and multiple therapies, she underwent FoundationOne®Liquid CDx NGS testing (Foundation Medicine, Cambridge, MA, USA, https://www.foundationmedicine.com/ ), which identified PTEN I101N, ESR1 Y537N and D538G, CDH1 F810fs, and PIK3CA E545K mutations (Fig. ).

Techniques: Mutagenesis

a A FoundationOne®Liquid CDx testing that was collected via blood draw on Patient 2. PTEN I101N, ESR1 Y537N and D538G, CDH1 F810fs, and PIK3CA E545K mutations were found (Collection date December 19, 2018). b A FoundationOne®CDx testing from a tissue bone biopsy that was performed after academic center consultation. PTEN I101N, ESR1 Y537N, CDH1 F810fs, and PIK3CA E545K mutations, TMB-4Mut/Mb, and Microsatellite-stable were reported (collection date: January 21, 2019).

Journal: Case Reports in Oncology

Article Title: Utilizing Liquid Biopsy for Treatment Management in Bone-Dominant Metastatic Breast Cancer: A Case Report

doi: 10.1159/000526642

Figure Lengend Snippet: a A FoundationOne®Liquid CDx testing that was collected via blood draw on Patient 2. PTEN I101N, ESR1 Y537N and D538G, CDH1 F810fs, and PIK3CA E545K mutations were found (Collection date December 19, 2018). b A FoundationOne®CDx testing from a tissue bone biopsy that was performed after academic center consultation. PTEN I101N, ESR1 Y537N, CDH1 F810fs, and PIK3CA E545K mutations, TMB-4Mut/Mb, and Microsatellite-stable were reported (collection date: January 21, 2019).

Article Snippet: After another 4 years and multiple therapies, she underwent FoundationOne®Liquid CDx NGS testing (Foundation Medicine, Cambridge, MA, USA, https://www.foundationmedicine.com/ ), which identified PTEN I101N, ESR1 Y537N and D538G, CDH1 F810fs, and PIK3CA E545K mutations (Fig. ).

Techniques: